CASP1 and early-onset autosomal dominant Alzheimer disease: Previous studies have demonstrated that caspase-1 activation and subsequent cleavage of GSDMD exert a crucial effect on pyroptosis and neuroinflammation in central nervous system (CNS) diseases such as cerebral ischemia and Alzheimer’s disease, and inhibiting Caspase-1 activation could mitigate brain injury (15–18).